BridgeMD
Compares treatment options for Allergic Transfusion Reaction
Official title Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
ClinicalTrials.gov ID: NCT04688736
What this study is testing
What is Chlorpheniramine?
Chlorpheniramine is an investigational medicine, being studied as a potential treatment for allergic transfusion reaction.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- 18\~65 years old.
- Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen...
- Subject can fully understand and voluntarily sign informed consent forms.
You likely can't join if
- Subject with a history of allergic diseases.
- Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
- Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
- Subject transfused with washed RBC.
- Received allo-HSCT transplantation before.
- Subject with heart failure.
See the full eligibility criteria
- 18\~65 years old.
- Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.
- Subject can fully understand and voluntarily sign informed consent forms.
- Subject with a history of allergic diseases.
- Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
- Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
- Subject transfused with washed RBC.
- Received allo-HSCT transplantation before.
- Subject with heart failure.
- Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
- Pregnant or nursing women.
- Inability to understand or to follow study procedures.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
- Zhoukou, Henan, China
- Tai’an, Shandong, China
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China; Zhoukou, Henan, China; Tai’an, Shandong, China; Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.